Business Context and Reporting Period
Company: pSivida Corp. (Note: Request metadata listed "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 8-K (Current Report)
Date of Report: January 18, 2011
Purpose: Update to Risk Factors regarding capital needs, regulatory status of lead product Iluvien, and financial history.
Key Financial Metrics
- Liquidity: Cash, cash equivalents, and marketable securities totaled approximately $15.3 million as of September 30, 2010.
- Runway: Management believes current funds are sufficient to operate into at least calendar year 2012.
- Profitability History:
- Fiscal 2010 (ended June 30, 2010): Net income of $8.8 million (driven by a $15.0 million accelerated payment from Alimera).
- Fiscal 2009: Net loss of $2.5 million.
- Fiscal 2008: Net loss of $75.7 million.
- Quarter ended September 30, 2010: Net loss of $3.1 million.
- Intangible Assets: $23.8 million on the balance sheet as of September 30, 2010 ($16.2 million BioSilicon, $7.6 million Durasert).
- Debt/Capital: No specific debt figures provided in this text; however, the company notes a history of losses and potential need for additional capital.
Material Changes and Operational Status
Regulatory Status of Iluvien (Lead Product):
- Event: The FDA issued a Complete Response Letter (CRL) in December 2010 regarding the New Drug Application (NDA) for Iluvien for Diabetic Macular Edema (DME).
- Outcome: The NDA could not be approved in its present form.
- Requirements: The FDA requested additional analyses of the 36-month clinical data (FAME Study), including exploratory analyses, and information regarding manufacturing controls and cGMP deficiencies found at third-party manufacturers.
- Next Steps: Alimera (licensee) is preparing 36-month data analyses and has requested a meeting with the FDA.
Financial Outlook: The company expects to incur losses in fiscal 2011 and the foreseeable future unless Iluvien is approved and successfully commercialized.
Guidance, Risks, and Contingencies
- Capital Needs: Future cash position depends significantly on FDA approval of Iluvien. If approval is delayed or denied, the company may need to seek additional capital, which may not be available on favorable terms.
- Revenue Contingency:
- Alimera has agreed to pay $25 million upon FDA approval of Iluvien for DME.
- pSivida is entitled to 20% of future profits on Iluvien sales (subject to offsets).
- Royalty income from Bausch & Lomb (Retisert/Vitrasert) is declining and not expected to be a material revenue source.
- Key Risks:
- Regulatory: No assurance that 36-month data will satisfy the FDA; potential delays of up to 36 months if carcinogenicity studies are required.
- Manufacturing: Deficiencies in cGMP at third-party manufacturers must be resolved.
- Accounting: Potential for future impairment charges on intangible assets ($23.8 million recorded) and non-cash charges related to warrant valuation fluctuations.
- Partnerships: Reliance on licensees (Alimera, Pfizer, Bausch & Lomb) who may terminate agreements or fail to commercialize products.
Investor Verification Checklist
- Verify the timeline for Alimera's resubmission of the Iluvien NDA following the December 2010 CRL.
- Confirm the status of cGMP remediation at Alimera's third-party manufacturing facilities.
- Monitor the company's cash burn rate to validate the "into 2012" liquidity runway.
- Review upcoming financial statements for potential impairment charges on the $23.8 million in intangible assets.
- Assess the impact of outstanding warrants (10.3 million) and options (2.9 million) on potential dilution.